Benralizumab: First Global Approval

Drugs
A Markham

Abstract

Kyowa Hakko Kirin, AstraZeneca and subsidiaries are developing benralizumab (Fasenra™)-a humanised anti-interleukin-5 receptor alpha chain (IL-5Rα) monoclonal antibody-as a treatment of severe eosinophilic asthma and chronic obstructive pulmonary disease (COPD). Eosinophilia is a characteristic of certain asthma and COPD phenotypes and depletion of eosinophils has demonstrated therapeutic benefit. Benralizumab was recently approved by the US FDA as add-on maintenance therapy for patients with severe asthma who have an eosinophilic phenotype. This article summarizes the milestones in the development of benralizumab leading to this first approval for the treatment of severe eosinophilic asthma.

References

May 12, 2009·The American Journal of Cardiology·José G Díez, Marc Cohen
Jun 2, 2010·The Journal of Allergy and Clinical Immunology·Roland KolbeckAnthony J Coyle
Jul 23, 2013·The Journal of Allergy and Clinical Immunology·Michel LavioletteNestor A Molfino
Dec 3, 2014·The American Journal of Emergency Medicine·Richard M NowakNestor A Molfino
Apr 21, 2016·International Archives of Allergy and Immunology·Hae-Sim ParkUNKNOWN Asian Benralizumab Study Group
Sep 11, 2016·Therapeutic Advances in Respiratory Disease·Francesco MenzellaLuigi Zucchi
Jan 22, 2017·CPT: Pharmacometrics & Systems Pharmacology·B WangL K Roskos
May 23, 2017·The New England Journal of Medicine·Parameswaran NairUNKNOWN ZONDA Trial Investigators
May 27, 2017·The Lancet. Respiratory Medicine·Gary T FergusonUNKNOWN BISE Study Investigators
Dec 7, 2017·The Journal of Asthma : Official Journal of the Association for the Care of Asthma·Bao-Ping TianWei Cui

❮ Previous
Next ❯

Citations

Jul 22, 2018·Expert Review of Clinical Pharmacology·Junyi Yang
May 31, 2019·Expert Opinion on Biological Therapy·Daniel EnnisChristian Pagnoux
Jan 11, 2020·Otology & Neurotology : Official Publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology·Kevin Chow, Maura K Cosetti
Nov 9, 2020·The Journal of Allergy and Clinical Immunology. in Practice·Leyla BarakatLuciana Kase Tanno
Feb 9, 2021·The World Allergy Organization Journal·Luciana Kase TannoMarco Caminati
Feb 25, 2021·Current Opinion in Allergy and Clinical Immunology·Luciana Kase Tanno, Pascal Demoly
Apr 15, 2021·Chemistry : a European Journal·Marta Ruiz-SantaquiteriaNazario Martín
Aug 26, 2021·Expert Opinion on Biological Therapy·Anurag Rathore, Himanshu Malani

❮ Previous
Next ❯

Related Concepts

Related Feeds

Asthma

This feed focuses in Asthma in which your airways narrow and swell. This can make breathing difficult and trigger coughing, wheezing and shortness of breath.

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.